A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 162 participants.

Also called NCT07448038

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 162 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07448038
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07448038. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-05 (actual); primary completion 2028-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Acronym
RIVULET
Condition
Atherosclerosis
Intervention (Drug)
Selnoflast
Intervention (Drug)
Placebo
Lead sponsor
Genentech, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07448038
Content hash
8c4a46cda6b972fa1e8a7227d63845610b303bb9b1bc185283e7365e9b096998